caudatin profile

caudatin: antineoplastic from Cynanchum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	21633059
CHEMBL ID	2023660
SCHEMBL ID	2461510
MeSH ID	M0572013

Synonym
caudatin
CHEMBL2023660
SCHEMBL2461510
38395-02-7
AKOS030573701
HY-N1983
[(3s,8s,9r,10r,12r,13s,14r,17s)-17-acetyl-3,8,14,17-tetrahydroxy-10,13-dimethyl-1,2,3,4,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-12-yl] (e)-3,4-dimethylpent-2-enoate
CS-0018304
DTXSID301319132
FS-10057

Research Excerpts

Overview

Caudatin is a potential antitumor agent isolated from the traditional Chinese medicine "baishouwu" It was the root tuber of Cynanchum auriculatum Royle ex Wight.

Excerpt	Reference	Relevance
"Caudatin is a potential antitumor agent isolated from the traditional Chinese medicine "baishouwu", which was the root tuber of Cynanchum auriculatum Royle ex Wight. "	( Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats. Ding, Y; Peng, Y, 2015)	2.11

Effects

Excerpt	Reference	Relevance
"Caudatin has been reported to trigger apoptosis in several types of cancer cell lines. "	( Caudatin induces cell apoptosis in gastric cancer cells through modulation of Wnt/β-catenin signaling. Ding, X; Hu, X; Li, X; Liu, X; Tan, Z; Xiang, S; Yang, C; Zhang, J; Zhang, X; Zhou, C; Zhou, J, 2013)	3.28

Treatment

Caudatin treatment also resulted in mitochondrial dysfunction which correlated with an imbalance of Bcl-2 family members. Treatment with caudatin also induced phosphorylation of extracellular-signal regulating kinase (ERK) and c-Jun N-terminal Kinase (JNK)

Excerpt	Reference	Relevance
"Caudatin treatment significantly decreased hsa_circ_0060927 expression but increased miR-421 and miR-195-5p expression."	( Hsa_circ_0060927 participates in the regulation of Caudatin on colorectal cancer malignant progression by sponging miR-421/miR-195-5p. Chen, J; Cheng, Y; Fang, M; Tang, X; Xu, L; Xue, Y, 2022)	1.69
"Caudatin treatment also resulted in mitochondrial dysfunction which correlated with an imbalance of Bcl-2 family members."	( Caudatin induces caspase-dependent apoptosis in human glioma cells with involvement of mitochondrial dysfunction and reactive oxygen species generation. Fan, CD; Fu, XT; Fu, XY; Gao, HL; Hou, YJ; Shao, LR; Sun, BL; Sun, JY; Yang, MF; Zhang, HF; Zhao, M; Zhu, LZ, 2016)	2.6
"Treatment with caudatin also induced phosphorylation of extracellular-signal regulating kinase (ERK) and c-Jun N-terminal kinase (JNK)."	( Caudatin induces cell cycle arrest and caspase-dependent apoptosis in HepG2 cell. Chen, G; Chen, HL; Fei, HR; Wang, FZ; Xiao, T, 2012)	2.16

Pharmacokinetics

Excerpt	Reference	Relevance
" Statistically significant differences were observed between conventional rats and diethylnitrosamine (DEN)-induced HCC rats with respect to pharmacokinetic parameters, including maximum concentration (Cmax), time to reach Cmax (Tmax), half-life (t1/2), area under the concentration-time curve (AUC0-t, AUC0-∞), mean residence time (MRT0-t and MRT0-∞), and oral clearance (CL/F)."	( Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats. Ding, Y; Peng, Y, 2015)	0.67
" The method was successfully applied to a pharmacokinetic study involving oral administration of caudatin to rats."	( Determination of Caudatin in Rat Plasma by UPLC-MS/MS: Application to a Preclinical Pharmacokinetic Study. Ge, RS; Hu, Y; Mao, B; Shan, Y; Wang, Y; Wu, X; Zhu, Q, 2015)	0.97

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay ID	Title	Year	Journal	Article
AID1453303	Cytotoxicity against human AD293 cells assessed as reduction in cell viability at 10 uM after 24 hrs by methylene blue dye based spectrophotometric method	2017	Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13	C
AID670447	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion by ELISA	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID659694	Selectivity ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HBeAg secretion	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID1888932	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Synthesis and biological evaluation of 3β-O-neoglycosides of caudatin and its analogues as potential anticancer agents.
AID670448	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion by ELISA	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID670449	Cytotoxicity against human HepG2(2.2.15) cells by modified-MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID659571	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by RT-PCR analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID659570	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HbeAg secretion by ELISA	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID659693	Selectivity ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2.2.15 cells assessed as suppression of HBsAg secretion	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID659692	Cytotoxicity against human HepG2(2.2.15) cells by MTT assay	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID670450	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral surface antigen secretion	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID659695	Selectivity ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID659569	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as suppression of HBsAg secretion by ELISA	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents.
AID1453300	Antagonist activity at TLR4 (unknown origin) expressed in human AD293 cells assessed as inhibition of LPS/ATP-stimulated TLR4/NF-kB signaling pathway at 10 uM after 16 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13	C
AID1444846	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA level	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
AID670451	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral e antigen secretion	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID1888929	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Synthesis and biological evaluation of 3β-O-neoglycosides of caudatin and its analogues as potential anticancer agents.
AID670453	Selectivity index, ratio of CC50 for human HepG2(2.2.15) cells to IC50 for Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID670452	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication by PCR analysis	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents.
AID1888930	Antiproliferative activity against human HCT-116 cells after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Synthesis and biological evaluation of 3β-O-neoglycosides of caudatin and its analogues as potential anticancer agents.
AID1888931	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 01-15, Volume: 54	Synthesis and biological evaluation of 3β-O-neoglycosides of caudatin and its analogues as potential anticancer agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (4.35)	29.6817
2010's	16 (69.57)	24.3611
2020's	6 (26.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (8.70%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	21 (91.30%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.11	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	3.25	1	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
diethylnitrosamine Diethylnitrosamine: A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties.. N-nitrosodiethylamine : A nitrosamine that is N-ethylethanamine substituted by a nitroso group at the N-atom.	2.57	2	nitrosamine	carcinogenic agent; hepatotoxic agent; mutagen
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	2.41	1	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
catechin Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.	7.6	1	catechin	antioxidant; plant metabolite
thiazoles [no description available]	2.07	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.25	1	benzamides; carboxylic ester
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.07	1	organic bromide salt	colorimetric reagent; dye
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.25	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
cucurbitacins [no description available]	2.6	1	11-oxo steroid
helioxanthin helioxanthin: structure in first source. helioxanthin : A furonaphthodioxole that is furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-7(9H)-one substituted by a 1,3-benzodioxol-5-yl group at posiiton 10. It is a inhibitor of HBV, HCV and HSV-1 viruses.	3.25	1	benzodioxoles; furonaphthodioxole; lignan	anti-HBV agent; antineoplastic agent; plant metabolite
tizoxanide tizoxanide: major metabolite of nitazoxanide; structure in first source	3.25	1	salicylamides
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.07	1	cinnamic acid	plant metabolite
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	2.48	2	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
bay 41-4109 BAY 41-4109: structure in first source	3.25	1
glycosides [no description available]	10.52	19
robustaflavone robustaflavone: bis-apigenin coupled at 6 and 3' positions; a potential non-nucleoside anti-hepatitis B agent;. robustaflavone : A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-3 of the hydroxyphenyl ring and C-6 of the chromene ring. Isolated from Thuja orientalis and Rhus succedanea it exhibits antioxidant, cytotoxic and anti-hepatitis B activity.	3.25	1	biflavonoid; hydroxyflavone; ring assembly	anti-HBV agent; antineoplastic agent; antioxidant; metabolite
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	3.25	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
helioxanthin 8-1 helioxanthin 8-1: an antiviral agent; structure in first source	3.25	1
beta-escin [no description available]	2.04	1

Condition	Relationship Strength	Studies
Chronic Hepatitis B [description not available]	3.06	1
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	3.06	1
Weight Gain Increase in BODY WEIGHT over existing weight.	7.31	1
Colorectal Cancer [description not available]	7.41	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.41	1
Astrocytoma, Grade IV [description not available]	2.6	1
Glial Cell Tumors [description not available]	2.87	3
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.6	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.87	3
Experimental Hepatoma [description not available]	2.25	1
Benign Neoplasms [description not available]	3.23	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.23	1
Breast Cancer [description not available]	7.21	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.21	1
Carcinoma, Anaplastic [description not available]	2.48	2
Cancer of Stomach [description not available]	2.08	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.48	2
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.08	1
Hepatocellular Carcinoma [description not available]	7.5	2
Cancer of Liver [description not available]	2.5	2
Metastase [description not available]	2.08	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.5	2
Liver Neoplasms Tumors or cancer of the LIVER.	2.5	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.08	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.11	1
Benign Neoplasms, Brain [description not available]	2.13	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.13	1
Cancer of Lung [description not available]	2.07	1
Angiogenesis, Pathologic [description not available]	2.07	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.07	1

caudatin

Description

Cross-References

Synonyms (10)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Bioassays (21)

Research

Studies (23)

Market Indicators

Research Demand Index: 22.27

Study Types

caudatin

Description

Cross-References

Synonyms (10)

Research Excerpts

Overview

Effects

Treatment

Pharmacokinetics

Bioassays (21)

Research

Studies (23)

Market Indicators

Research Demand Index: 22.27

Study Types

Related Drugs (20)

Related Conditions (30)